Filings · News reference
A recent SEC filing indicates that an insider at Quest Diagnostics Incorporated sold company shares valued at approximately $5.48 million.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
DOT Consortium has launched new return-to-duty and follow-up testing packages on its online compliance platform, which integrates with Quest Diagnostics' laboratory network.
Evercore ISI has updated its price target for Quest Diagnostics, raising it from $235 to $240.
Rothschild & Co Redburn has increased its price target for Quest Diagnostics Incorporated, moving it from $251 to $279.
Quest Diagnostics disclosed a cybersecurity incident involving unauthorized access to its Quanum Lab Services Manager platform, potentially impacting patient data.
Deutsche Bank has updated its price target for Quest Diagnostics, moving it from $232 to $245 while maintaining a 'Hold' rating.
Quest Diagnostics tops Q3 estimates, raises full-year 2026 guidance, and addresses an unauthorized Quanum LSM cybersecurity event.